Jennifer Doudna
Overview
Jennifer Doudna is a biochemist and angel investor based in Berkeley, California, renowned for her groundbreaking development of CRISPR-Cas9 as a genome engineering technology. She co-founded Caribou Biosciences in 2011, a company focused on CRISPR-Cas9 technologies for precision cell engineering. In addition to Caribou Biosciences, Doudna has co-founded several other biotechnology companies, including Scribe Therapeutics, Aurora Therapeutics, Intellia Therapeutics, and Mammoth Biosciences. She serves on the scientific advisory boards of these companies, guiding their strategic direction and research initiatives. Doudna's investment philosophy centers on supporting innovative companies that leverage CRISPR technology to advance genetic medicine and biotechnology. Her involvement in these ventures underscores her commitment to translating scientific discoveries into practical applications that address complex health challenges.
Portfolio Companies
Reach Jennifer Doudna directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Jennifer Doudna
What sectors does Jennifer Doudna invest in?
Jennifer Doudna invests in Software, Manufacturing, Robotics, Machine Learning, Biotechnology and Life Science, and is based in California, United States. Jennifer Doudna is listed as a angel investor in the ConnectSafely investor database.
What stage does Jennifer Doudna invest at?
Jennifer Doudna backs companies at Seed.
Which regions does Jennifer Doudna invest in?
Jennifer Doudna invests across United States.
What companies has Jennifer Doudna invested in?
Jennifer Doudna's portfolio includes Mammoth Biosciences, Caribou Biosciences, Intellia Therapeutics, Scribe Therapeutics and Aurora Therapeutics.
Last updated · Source: ConnectSafely investor database
